A.D.A.M. Innovations Strengthens Leadership Team to Accelerate Platform, Data and Digital Growth

Tokyo, Japan – September 2, 2026 – A.D.A.M. Innovations Co. (Japanese corporate name: Genesis Healthcare Co.), a leader in genomics, A.I., and data-driven healthcare innovation, today announced the appointments of Yasufumi Takao as Chief Commercial Officer, Platform & Data Services, and Ryan Mizuno as Chief Digital Officer within the company's A.D.A.M. Innovation Center.

The appointments reinforce A.D.A.M. Innovations' strategy to accelerate the commercialization of its AI and genomic data platforms while expanding its digital ecosystem.

As Chief Commercial Officer, Platform & Data Services, Yasufumi Takao will lead the commercial strategy, product growth, and market expansion of GeneLink, the company's genetics-powered ad-tech platform, and GenesisGaia, its genomic AI and data intelligence platform. He will be responsible for accelerating commercialization, developing strategic partnerships, and driving enterprise adoption of both platforms.

Yasufumi Takao brings more than 25 years of experience in business development, strategic partnerships, and commercial leadership across global technology companies. During his 14-year career at Google, he held senior commercial leadership roles supporting major enterprise customers and partner ecosystems. More recently, he helped drive AI- and wellness-related data platform initiatives, bringing extensive expertise at the intersection of AI, data, digital health, and platform commercialization.

Ryan Mizuno joins as Chief Digital Officer, where he will lead the evolution of A.D.A.M. Innovations' digital customer experience, e-commerce strategy, and digital platforms across the GeneLife ecosystem. He will oversee online commerce and customer experience initiatives designed to expand consumer access to personalized genomic services while driving customer acquisition, engagement, and retention.

Mizuno brings more than two decades of experience spanning financial services, digital transformation, marketing technology, CRM, and e-commerce. His career includes leadership positions at Tapestry, SAP, MRM, Wunderman, Nomura Securities, and JPMorgan Chase, providing a unique combination of expertise from both global brands and leading digital agencies.

"Yasufumi Takao and Ryan Mizuno bring highly complementary capabilities that will significantly strengthen our A.D.A.M. Innovation Center as we continue building A.D.A.M. Innovations into a global leader in genomics, AI, and data-driven platforms," said Michel Mommejat, President and Chief Innovation Officer of A.D.A.M. Innovations.

"Takao's experience in commercializing advertising, and enterprise data platforms will accelerate the growth of GeneLink and GenesisGaia, while Mizuno's expertise in digital transformation, customer engagement, and e-commerce will further strengthen our consumer ecosystem. Together, they will play a pivotal role in expanding our AI-powered platforms and delivering the next generation of personalized health and genomic intelligence solutions."

These appointments reflect A.D.A.M. Innovations' continued investment in world-class leadership as the company accelerates the commercialization of its proprietary genomic data assets, AI technologies, and digital health platforms across Japan and international markets.

About A.D.A.M. Innovations Co.

Founded in 2004 in Tokyo, A.D.A.M. Innovations Co. (Japanese corporate name: Genesis Healthcare Co.) is building the world's leading genomic intelligence platform by integrating genomics, multimodal biological and health data, artificial intelligence, and secure data technologies to transform data into actionable solutions. Leveraging one of Japan's largest genomic datasets, the Company develops technologies that advance healthcare and drive innovation across life sciences, pharmaceuticals, consumer industries, agriculture, and research. Having conducted more than 2.9 million genetic tests, A.D.A.M. Innovations maintains the largest R&D genomic database of the Japanese population.  A.D.A.M. Innovations is committed to advancing personalized healthcare, precision medicine, scientific discovery, and the future of human health, while making a meaningful impact on people's lives.

For additional information, visit www.adam-innovations.com

Corporate media contact:

Email: press@adam-innovations.com